Prognostic and Predictive Value of Complete Blood Count Parameters in Patients with NSCLC Treated with PD-1 Inhibitors

被引：0
|
作者：
Tourkantonis, I. [1 ]
Grapsa, D. [1 ]
Charpidou, A. [1 ]
Gkiozos, I. [1 ]
Gogas, H. [2 ]
Psyrri, D. [3 ]
Syrigos, K. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Internal Med 3, Sch Med, Oncol Unit, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 1, Oncol Unit, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 2, Oncol Unit, Athens, Greece
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Advanced non-small cell lung cancer; PD-1; inhibitors; complete blood count parameters;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P33.13
引用
收藏
页码：S410 / S411
页数：2
相关论文
共 50 条
  • [31] Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
    Arbour, Kathryn C.
    Luu, Anh Tuan
    Luo, Jia
    Rizvi, Hira
    Plodkowski, Andrew J.
    Sakhi, Mustafa
    Huang, Kevin B.
    Digumarthy, Subba R.
    Ginsberg, Michelle S.
    Girshman, Jeffrey
    Kris, Mark G.
    Riely, Gregory J.
    Yala, Adam
    Gainor, Justin F.
    Barzilay, Regina
    Hellmann, Matthew D.
    CANCER DISCOVERY, 2021, 11 (01) : 59 - 67
  • [32] ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
    Wei Nie
    Zhi-Jie Wang
    Kai Zhang
    Bing Li
    Yi-Ran Cai
    Feng-Cai Wen
    Ding Zhang
    Yue-Zong Bai
    Xue-Yan Zhang
    Shu-Yuan Wang
    Lei Cheng
    Hua Zhong
    Li Liu
    Jie Wang
    Bao-Hui Han
    BMC Medicine, 20
  • [33] Prognostic value of PD-L1+CD4+T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.
    Vetsika, Kiriaki E.
    Aggouraki, Despoina
    Lyristi, Zacharoula
    Koinis, Filippos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [34] ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
    Nie, Wei
    Wang, Zhi-Jie
    Zhang, Kai
    Li, Bing
    Cai, Yi-Ran
    Wen, Feng-Cai
    Zhang, Ding
    Bai, Yue-Zong
    Zhang, Xue-Yan
    Wang, Shu-Yuan
    Cheng, Lei
    Zhong, Hua
    Liu, Li
    Wang, Jie
    Han, Bao-Hui
    BMC MEDICINE, 2022, 20 (01)
  • [35] Exploring the predictive value of complete blood count inflammatory parameters in early pregnancy for missed abortion
    Huang, Lingna
    Wang, Jiaran
    Yan, Lebin
    Wang, Jingjing
    Xiong, Xiumei
    SCIENCE PROGRESS, 2025, 108 (01)
  • [36] PROGNOSTIC VALUE OF EXPRESSION OF PD-1 AND CTLA-4 IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Eun, Hyuk Soo
    Lee, Tae Hee
    Lee, Jeongdong
    Kim, Min Seok
    Rou, Woo Sun
    Jeon, Hong Jae
    Kim, Seok Hyun
    Lee, Byung Seok
    Choi, Hei-Gwon
    Kim, Ha Neul
    Jang, Tae Min
    Lee, Ji Ah
    Son, Chae Yeon
    Bu, Jiyoon
    HEPATOLOGY, 2023, 78 : S1879 - S1880
  • [37] Predictive Value of the Complete Blood Count (CBC) in Neonatal Sepsis
    Mirta, Mesquita
    Sonia, Avalos
    Laura, Godoy
    Elizabeth, Alvarez
    PEDIATRIA-ASUNCION, 2011, 38 (01): : 23 - 30
  • [38] Prognostic value of systemic inflammation response index (SIRI) in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: A meta-analysis
    Gu, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S1585 - S1586
  • [39] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
    Castello, Angelo
    Rossi, Sabrina
    Toschi, Luca
    Mansi, Luigi
    Lopci, Egesta
    CANCERS, 2020, 12 (06)
12345